CTOs on the Move

Quadrant Biosciences

www.quadrantbiosciences.com

 
Quadrant Biosciences is an epigenetic diagnostics company with a focus on the early detection of neurological disorders and other large-scale health issues. Revolutionary advancements in the early detection of autism spectrum disorder, Parkinson’s disease, and mTBI, through the application of the Clarifi® epigenetic diagnostic platform, could have a significant impact on the way clinicians approach the diagnosis and treatment of these serious conditions. In March 2020, we made the decision to pivot and allocate some of our resources to directly address the pandemic. By leveraging our expertise in RNA analysis, we have been able to be part of ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Charles Marra
Vice President of Technology Profile
Nick Gianadda
Chief Technology Officer Profile

Similar Companies

Bio-Path Holdings

Bio-Path is a biotechnology company developing targeted therapies for acute myeloid leukemia (AML), chronic myeloid leukemia (CML) and other challenging cancers. The company`s lead product candidate, prexigebersen (Liposomal Grb2 Antisense), formerly BP1001, is currently being assessed in a Phase 2 clinical study in 54 people with previously untreated AML who are not eligible for or who have decided to forego intensive induction therapy because of their age or fragile health.

Xpention Genetics Inc

Xpention Genetics Inc is a Conifer, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Xpogen

Xpogen is a Newton Center, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ATAI Life Sciences

Bridging the gap between what the #mentalhealth system can provide and what people need. Interested in #psychedelics, #drugdevelopment, and #AI. CEO @FloBrand.

Chiesi USA

Chiesi USA, Inc., headquartered in Cary, NC, is a specialty pharmaceutical company focused on commercializing products for the hospital and adjacent specialty markets. Key elements of the Company’s strategy are to focus its commercial and development efforts in the hospital and adjacent specialty product sector within the U.S. pharmaceutical marketplace; continue to seek out opportunities to acquire companies, marketed or registration-stage products and late-stage development products that fit within the Company’s focus areas; and generate revenues by marketing approved generic products through the Company’s wholly-owned subsidiary, Aristos Pharmaceuticals, Inc. Chiesi USA, Inc. is a wholly-owned subsidiary of Chiesi Farmaceutici S.p.A.